Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 24 | 2022 | 167 | 5.070 |
Why?
|
| Anti-HIV Agents | 14 | 2022 | 45 | 3.490 |
Why?
|
| Pre-Exposure Prophylaxis | 16 | 2022 | 43 | 2.520 |
Why?
|
| HIV-1 | 3 | 2018 | 17 | 1.310 |
Why?
|
| Medication Adherence | 12 | 2022 | 36 | 1.230 |
Why?
|
| Homosexuality, Male | 12 | 2022 | 41 | 1.070 |
Why?
|
| Tenofovir | 4 | 2021 | 8 | 0.900 |
Why?
|
| Transgender Persons | 7 | 2022 | 12 | 0.860 |
Why?
|
| Adenine | 3 | 2019 | 4 | 0.730 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 58 | 0.720 |
Why?
|
| Humans | 24 | 2022 | 4931 | 0.710 |
Why?
|
| Emtricitabine | 4 | 2022 | 5 | 0.690 |
Why?
|
| Rilpivirine | 1 | 2018 | 1 | 0.610 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 1 | 0.610 |
Why?
|
| Tablets | 1 | 2018 | 3 | 0.610 |
Why?
|
| Mentoring | 1 | 2018 | 12 | 0.590 |
Why?
|
| Patient Participation | 1 | 2018 | 23 | 0.580 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 6 | 0.520 |
Why?
|
| Adult | 14 | 2021 | 1402 | 0.500 |
Why?
|
| Male | 17 | 2022 | 2620 | 0.500 |
Why?
|
| Sexual and Gender Minorities | 4 | 2022 | 20 | 0.420 |
Why?
|
| Sexual Behavior | 4 | 2022 | 49 | 0.410 |
Why?
|
| Sexual Partners | 3 | 2019 | 23 | 0.360 |
Why?
|
| Female | 11 | 2022 | 2964 | 0.340 |
Why?
|
| Unsafe Sex | 2 | 2020 | 9 | 0.330 |
Why?
|
| Text Messaging | 4 | 2022 | 12 | 0.320 |
Why?
|
| Middle Aged | 6 | 2021 | 1544 | 0.250 |
Why?
|
| Risk-Taking | 3 | 2019 | 43 | 0.230 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2022 | 12 | 0.230 |
Why?
|
| California | 3 | 2022 | 161 | 0.230 |
Why?
|
| Motivational Interviewing | 1 | 2022 | 4 | 0.200 |
Why?
|
| Gender-Based Violence | 1 | 2022 | 2 | 0.200 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 7 | 0.200 |
Why?
|
| Syphilis | 1 | 2022 | 4 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2022 | 15 | 0.190 |
Why?
|
| Organophosphates | 2 | 2019 | 2 | 0.190 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 146 | 0.180 |
Why?
|
| Monitoring, Ambulatory | 1 | 2019 | 5 | 0.160 |
Why?
|
| Drug Compounding | 1 | 2019 | 2 | 0.160 |
Why?
|
| Primary Prevention | 1 | 2019 | 21 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 124 | 0.160 |
Why?
|
| Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2019 | 2 | 0.160 |
Why?
|
| Bone Remodeling | 1 | 2019 | 6 | 0.160 |
Why?
|
| Oxazines | 1 | 2018 | 2 | 0.150 |
Why?
|
| Pyridones | 1 | 2018 | 3 | 0.150 |
Why?
|
| Vitamin D | 1 | 2019 | 35 | 0.150 |
Why?
|
| Drug Tolerance | 1 | 2018 | 25 | 0.150 |
Why?
|
| Piperazines | 1 | 2018 | 17 | 0.150 |
Why?
|
| Standard of Care | 1 | 2018 | 1 | 0.150 |
Why?
|
| Lost to Follow-Up | 1 | 2018 | 2 | 0.150 |
Why?
|
| Enema | 1 | 2018 | 2 | 0.150 |
Why?
|
| Gonorrhea | 1 | 2018 | 2 | 0.150 |
Why?
|
| Therapeutic Irrigation | 1 | 2018 | 3 | 0.150 |
Why?
|
| Chlamydia Infections | 1 | 2018 | 6 | 0.150 |
Why?
|
| Rectum | 1 | 2018 | 7 | 0.150 |
Why?
|
| Health Personnel | 1 | 2018 | 40 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 62 | 0.150 |
Why?
|
| Young Adult | 4 | 2020 | 382 | 0.140 |
Why?
|
| Depression | 1 | 2018 | 97 | 0.140 |
Why?
|
| Prodrugs | 1 | 2017 | 2 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 11 | 0.140 |
Why?
|
| Bone Density | 1 | 2017 | 16 | 0.130 |
Why?
|
| Kidney | 1 | 2017 | 165 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 202 | 0.110 |
Why?
|
| United States | 3 | 2021 | 764 | 0.110 |
Why?
|
| Incidence | 2 | 2022 | 141 | 0.090 |
Why?
|
| Adolescent | 2 | 2021 | 569 | 0.080 |
Why?
|
| Viral Load | 1 | 2022 | 11 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 18 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 5 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2022 | 8 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 37 | 0.050 |
Why?
|
| Prevalence | 1 | 2022 | 184 | 0.050 |
Why?
|
| Focus Groups | 1 | 2020 | 33 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 25 | 0.040 |
Why?
|
| Condoms | 1 | 2020 | 14 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 44 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 26 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 32 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 93 | 0.040 |
Why?
|
| Los Angeles | 1 | 2020 | 244 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 69 | 0.040 |
Why?
|
| Capsules | 1 | 2019 | 1 | 0.040 |
Why?
|
| Wireless Technology | 1 | 2019 | 1 | 0.040 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 2 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 36 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 22 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 53 | 0.040 |
Why?
|
| Deglutition | 1 | 2019 | 40 | 0.040 |
Why?
|
| Procollagen | 1 | 2019 | 1 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2019 | 19 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 59 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 40 | 0.040 |
Why?
|
| Directive Counseling | 1 | 2019 | 3 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 12 | 0.040 |
Why?
|
| Logistic Models | 1 | 2019 | 117 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 3 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2019 | 38 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 55 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 39 | 0.040 |
Why?
|
| Chlamydia | 1 | 2018 | 2 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 58 | 0.040 |
Why?
|
| Rectal Diseases | 1 | 2018 | 2 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2019 | 229 | 0.040 |
Why?
|
| Biomarkers | 1 | 2019 | 160 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2019 | 513 | 0.040 |
Why?
|
| Risk Factors | 1 | 2019 | 593 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 224 | 0.030 |
Why?
|